Protagonist Therapeutics Inc (PTGX)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 675,295 | 336,677 | -536,755 | -409,362 | -283,811 |
| Debt-to-capital ratio | 0.00 | 0.00 | — | — | — |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $675,295K)
= 0.00
Based on the provided data, Protagonist Therapeutics Inc had a debt-to-capital ratio of 0.00 as of December 31, 2023 and December 31, 2024. This indicates that the company had no debt in relation to its total capital during these two years. A debt-to-capital ratio of zero typically suggests a conservative financial structure, with the company relying more on equity financing rather than debt to fund its operations and growth. This can be viewed positively by investors and creditors as it signifies lower financial risk and higher financial stability for the company. It is important to note that the absence of debt in the capital structure could also mean potentially limited tax benefits from interest deductions but may reduce the company's overall financial risk. Additional information on the company's financing activities and future plans would provide a more comprehensive understanding of its overall financial health and strategy.
Peer comparison
Dec 31, 2024